The Swiss pharmaceutical group Novartis announced today that clinical trials of the drug ruxolitinib did not show improvement in the treatment of severe cases of covid-19.
"The third phase study (the last phase of human trials) did not have the expected result in terms of reducing the number of hospitalizations of patients with covid-19 who had serious complications," Novartis said.
That group, however, adds that it continues to work to analyze the results in order to better understand covid-19.
The group specifies that the inability of ruxolitinib to improve the condition of patients with covid-19 "did not affect the current trials of other diseases".
Bonus video:
